Does a care coordination program improve the detection and treatment of co-morbid depression in patients with COPD?
What is the impact of screening for depression on outcomes of patients with COPD?
Does a protocol-based screening for commonly occurring comorbid conditions in patients with COPD (eg. CAD, CHF, depression, sleep apnea) improve management and outcomes for patients with COPD?
How can we create precision diagnostics for COPD in practice settings that will help inform the transition from screening to better diagnosis and treatment strategies and that will help identify patients or communities at highest risk for unrecognized or over diagnosed COPD.
What is needed to improve access to quality neonatal health care in order to get a more accurate idea of CHD prevalence in children, especially in underrepresented populations and those with limited access to primary care?
What role could safety net programs and community health centers play with screening (and subsequent treatment, education)?
Currently, there are limited, if none, funding resources to synthesize and screen potentially therapeutic molecules, based on supportive findings in cells, biopsy tissues from the patients with the disease in question, and the preliminary data to support the development of a series of compounds to screen them for their pharmacokinetics, pharmacodynamics, toxicity and use in clinically-relevant large animal models.